Checkpoint Inhibition in Renal Cell Carcinoma

Video

For High-Definition, Click

The role of checkpoint inhibition in renal cell carcinoma (RCC) is less clear than in other tumor types. A multitude of targeted therapies are approved for RCC, with extensive detail paid to sequencing these treatments for optimal results. At this point, it is unclear where a checkpoint inhibitor could fit into this treatment landscape, Robert Dreicer, MD, suggests.

In a phase II dose-finding study, patients with RCC who received the PD-1 inhibitor nivolumab experienced a median progression-free survival (PFS) of approximately 4 months. The objective response rate was near 20%, with a stable disease rate between 37% and 44% at the time of the analysis. A phase III trial is currently comparing nivolumab with the mTOR inhibitor everolimus in 822 patients with advanced or metastatic clear cell RCC who have received 2 prior antiangiogenic. The primary endpoint of this study is overall survival (OS), with PFS as a secondary outcome measure.

Many of the approvals in RCC were based on PFS as an endpoint, since OS can be a difficult endpoint to measure, notes Dreicer. Moreover, early trials have suggested that the level of single-agent activity with nivolumab may not be sufficient for regulatory approval, warranting the exploration of combination approaches.

Nivolumab was explored in combination with the CTLA-4 inhibitor ipilimumab in a phase Ib study. With the combination, the ORR was 43% to 48% based on dose size. The median PFS was not reached, with a 24-week rate of approximately 65%. A phase II study is currently recruiting that will examine single-agent nivolumab versus either nivolumab with bevacizumab or ipilimumab as a treatment for patients with metastatic RCC (NCT02210117).

The issue with combination strategies will be toxicity, which could result in shorter treatment duration. Ideally, as a single-agent, a checkpoint inhibitor could be used to replace a more toxic agent. A potential strategy could be to replace IL-2 with a checkpoint inhibitor, suggests Omid Hamid, MD.

Related Videos
D. Ross Camidge, MD, PhD
D. Ross Camidge, MD, PhD
D. Ross Camidge, MD, PhD
Manmeet Singh Ahluwalia, MD
D. Ross Camidge, MD, PhD
D. Ross Camidge, MD, PhD
Sangeeta Goswami, MD, PhD, of The University of Texas MD Anderson Cancer Center
Pasi A. Jänne, MD, PhD, discusses an exploratory analysis from the FLAURA2 trial of osimertinib plus chemotherapy in treatment-naive, EGFR-mutant NSCLC.
Andrew Ip, MD